Navigation Links
Amilpar - Distribution of Interest on Capital Stock
Date:12/29/2009

RIO DE JANEIRO, Dec. 29 /PRNewswire-FirstCall/ -- Amilpar (Bovespa: AMIL3; Bloomberg: AMIL3 BZ and APAR < GO >; Reuters: AMIL3.SA), the largest managed care organization in Brazil, informs its Shareholders that the Board of Directors of the Company, in a meeting held today, approved the payment of Interest on Capital Stock in the gross amount of R$ 0.0168 per common share, corresponding to the total amount of R$ 6.0 million. The payment will be made on April 30, 2010, based on shareholders' position as of December 29, 2009.

Except for exempt shareholders under applicable legislation, the payment of Interest on Capital Stock will have deducted 15% (fifteen per cent) for Income Tax, resulting in net Interest of R$ 0.0143 per common share. The shareholders exempt from Tax Withholding must confirm this status by mailing the corresponding documents to the following address no later than January 5, 2010:

    Amilpar - Relacoes com Investidores (Investor Relations)
    Av. das Americas, 4,200 - Bl. 3 - 4th Floor - Barra da Tijuca
    Rio de Janeiro - RJ - Postal Code 22640-907

The Company will consider the shareholder not tax-exempt if the above- mentioned documents are not received by the aforementioned date.

The Interest on Capital Stock will be attributed to the minimum mandatory dividend relative to the fiscal year ending December 31, 2009 for its net amount, after the deduction of Income Tax, as per Paragraph 7, article 9 of the Brazilian Corporate Law # 9,249/95, and in item V of CVM Deliberation 207/96.

Please note that shares acquired on or after December 30, 2009 will be traded Ex-Interest on Capital Stock.

To access the Notice to Shareholders, visit our website at www.amilpar.com.br/ir

    IR Contact
    Erwin Kleuser
    Investor Relations Officer
    Phone: +55 (21) 3805-1155
    invest@amil.com.br
    www.amilpar.com.br/ir

SOURCE Amilpar


'/>"/>
SOURCE Amilpar
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Amilpar - Relevant Fact
2. Amilpar - Press Release - Commercial Papers
3. Amilpar - Relevant Fact - Public Offer
4. Amilpar - Revenues Grow 8% and Net Income Improves 28% in 3Q09
5. Amilpar - Operating Revenues Grew 9% in the Second Quarter and 11% in the First Half of 2009
6. Amilpar - Revenue Increases 13.4% and Medical Loss Ratio Falls in the First Quarter 2009
7. Amilpar - Revenues Increase by 26.5% and Adjusted Net Income Climbs 28.7% in 2008
8. Amilpar - Notice to Shareholders - Distribution of Interest on Capital Stock
9. Amilpar Revenues Grow 28% in the First 9 Months of 2008 and 4.5% Over Previous Quarter
10. Amilpar Revenues Increase by 32% and EBITDA Doubles in 2007
11. Grubb & Ellis Healthcare REIT II Declares Initial Distribution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... today announced the release of two biometric time and attendance tracking products: the ... 4.0 software. NCheck Cloud Bio Attendance uses biometric face recognition to enable ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... work, the Self-Funding Success website has recently developed and published an informational resource ... ” was created based on common inquiries the site’s team of third party ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... desire to achieve the “perfect smile.” The National Association of Dental Laboratories (NADL) ... what dentists should be aware of when utilizing dental laboratories and technicians that ...
(Date:3/28/2017)... ... March 28, 2017 , ... Public relations pros work hard to earn placements ... channels. , While many results are clear, much of PR is hard to quantify. ... it comes to measurement, firms should always take an all-inclusive approach that takes both ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Silicon Valley Hair ... to announce a new blog post about women’s hair loss. Although hair transplant procedures ... loss as they age. Menopause or genetics can be two reasons a woman may ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... BETHESDA, Md. , March 27, 2017  ImMAGE ... that its immunotherapy successfully passed early toxicology and efficacy ... immune system to target a specific protein, MAGE A, ... triple negative breast cancer. After 4 ... was able to show very little toxicity in a ...
(Date:3/27/2017)... SAN MATEO, Calif. , March 27, 2017 ... has been acquired by Ethicon, a division of ... Reflux Management System for the treatment of gastro-esophageal ... on magnetic sphincter augmentation (MSA) technology and the ... European medical centers. Torax Medical was ...
(Date:3/27/2017)... , March 27, 2017 BioLineRx ... and immunology, announced today that AGI-134, an immunotherapy for the ... of Agalimmune Ltd., will be featured at the upcoming ... Washington, DC to be held on ... ...
Breaking Medicine Technology: